Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.31 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5367080 | 1.00 | POLB (0.38) | POLBLMNAALDH1A1HSD17B10OPRM1 | |
| SCHEMBL6026943 | 0.84 | LMNA (0.38) | POLBLMNAALDH1A1HSD17B10OPRM1 | |
| SCHEMBL5370829 | 0.81 | MEN1 (0.31) | — | |
| SCHEMBL5370833 | 0.81 | MEN1 (0.31) | — | |
| SCHEMBL5362004 | 0.80 | POLB (0.35) | POLBLMNAALDH1A1HSD17B10OPRM1 | |
| SCHEMBL5361996 | 0.80 | POLB (0.35) | POLBLMNAALDH1A1HSD17B10OPRM1 | |
| SCHEMBL5381062 | 0.80 | POLB (0.35) | POLBLMNAALDH1A1HSD17B10OPRM1 | |
| SCHEMBL5381059 | 0.80 | POLB (0.35) | POLBLMNAALDH1A1HSD17B10OPRM1 | |
| SCHEMBL18410218 | 0.79 | POLB (0.37) | POLBLMNAALDH1A1HSD17B10OPRM1 | |
| SCHEMBL5370001 | 0.78 | MEN1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276622-B2 | Method for producing oxygen-containing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-10-02 | — | — | US | disclosed |
| US-20060173221-A1 | Method for producing oxygen-containing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1609777-A1 | METHOD FOR PRODUCING OXYGEN-CONTAINING COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173221-A1 | Method for producing oxygen-containing compound | GPX4, DUOX2, SCO2 | POLB 532/4885LMNA 4036/4885ALDH1A1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.